Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1997 1
1998 2
1999 2
2000 3
2001 1
2002 5
2003 1
2004 3
2005 4
2006 10
2007 8
2008 15
2009 20
2010 16
2011 8
2012 11
2013 6
2014 9
2015 12
2016 9
2017 12
2018 10
2019 5
2020 10
Text availability
Article attribute
Article type
Publication date

Search Results

162 results
Results by year
Filters applied: . Clear all
Page 1
Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions.
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Dekkers O, Popovic V, Wierinckx A, McCormack A, Petersenn S, Burman P, Raverot G, Villa C. Trouillas J, et al. Among authors: Petersenn S. Rev Endocr Metab Disord. 2020 Jun;21(2):243-251. doi: 10.1007/s11154-020-09562-9. Rev Endocr Metab Disord. 2020. PMID: 32504268 Review.
Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A, Bronstein MD, Schopohl J, Delibasi T, Salvatori R, Li Y, Barkan A, Suzaki N, Tauchmanova L, Ortmann CE, Ravichandran S, Petersenn S, Pivonello R. Lacroix A, et al. Among authors: Petersenn S. J Endocrinol Invest. 2020 May 8. doi: 10.1007/s40618-020-01246-0. Online ahead of print. J Endocrinol Invest. 2020. PMID: 32385851
Diagnosis and management of prolactinomas: current challenges.
Petersenn S, Giustina A. Petersenn S, et al. Pituitary. 2020 Feb;23(1):1-2. doi: 10.1007/s11102-019-01025-y. Pituitary. 2020. PMID: 31900881 No abstract available.
Biochemical diagnosis in prolactinomas: some caveats.
Petersenn S. Petersenn S. Pituitary. 2020 Feb;23(1):9-15. doi: 10.1007/s11102-019-01024-z. Pituitary. 2020. PMID: 31873848 Review.
[Hypoparathyroidism - un underestimated problem?].
Petersenn S, Bojunga J, Brabant G, Etzrodt-Walter G, Finke R, Scharla S, Stamm B, Weber MM, Wicke C, Siggelkow H. Petersenn S, et al. MMW Fortschr Med. 2019 Dec;161(Suppl 7):12-20. doi: 10.1007/s15006-019-1174-4. MMW Fortschr Med. 2019. PMID: 31828671 Review. German.
Management of Aggressive Pituitary Tumors - A 2019 Update.
Petersenn S. Petersenn S. Horm Metab Res. 2019 Dec;51(12):755-764. doi: 10.1055/a-1060-1883. Epub 2019 Dec 11. Horm Metab Res. 2019. PMID: 31826270 Review.
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease.
Newell-Price J, Pivonello R, Tabarin A, Fleseriu M, Witek P, Gadelha MR, Petersenn S, Tauchmanova L, Ravichandran S, Gupta P, Lacroix A, Biller BMK. Newell-Price J, et al. Among authors: Petersenn S. Eur J Endocrinol. 2020 Feb;182(2):207-217. doi: 10.1530/EJE-19-0695. Eur J Endocrinol. 2020. PMID: 31804965 Free PMC article. Clinical Trial.
Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, Deutschbein T, Unger N, Lammert A, Topuzoglu-Müller T, Bojunga J, Droste M, Johanssen S, Kolenda H, Ritzel K, Buslei R, Strasburger CJ, Petersenn S, Honegger J. Elbelt U, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2020 Mar 1;105(3):dgz211. doi: 10.1210/clinem/dgz211. J Clin Endocrinol Metab. 2020. PMID: 31746334
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.
Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S. Giustina A, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz096. doi: 10.1210/clinem/dgz096. J Clin Endocrinol Metab. 2020. PMID: 31606735 Free article.
Clinical Situation, Therapy, and Follow-Up of Adult Craniopharyngioma.
Mende KC, Kellner T, Petersenn S, Honegger J, Evangelista-Zamora R, Droste M, Stalla G, Deutschbein T, Wang Y, Moskopp D, Knappe U, Schilbach K, Flitsch J. Mende KC, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz043. doi: 10.1210/clinem/dgz043. J Clin Endocrinol Metab. 2020. PMID: 31589293
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study.
Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T'Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J. Fleseriu M, et al. Among authors: Petersenn S. Clin Endocrinol (Oxf). 2019 Dec;91(6):776-785. doi: 10.1111/cen.14081. Epub 2019 Oct 1. Clin Endocrinol (Oxf). 2019. PMID: 31465533 Free PMC article.
Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?
Petersenn S, Christ-Crain M, Droste M, Finke R, Flitsch J, Kreitschmann-Andermahr I, Luger A, Schopohl J, Stalla G. Petersenn S, et al. Geburtshilfe Frauenheilkd. 2019 Apr;79(4):365-374. doi: 10.1055/a-0794-7587. Epub 2019 Mar 6. Geburtshilfe Frauenheilkd. 2019. PMID: 31000881 Free PMC article.
MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis.
Bonneville F, Rivière LD, Petersenn S, Bevan J, Houchard A, Sert C, Caron PJ; PRIMARYS Study group. Bonneville F, et al. Among authors: Petersenn S. Eur J Endocrinol. 2018 Dec 1:EJE-18-0254.R2. doi: 10.1530/EJE-18-0254. Online ahead of print. Eur J Endocrinol. 2018. PMID: 30540560
Black swans - neuroendocrine tumors of rare locations.
Koch CA, Petersenn S. Koch CA, et al. Among authors: Petersenn S. Rev Endocr Metab Disord. 2018 Jun;19(2):111-121. doi: 10.1007/s11154-018-9473-0. Rev Endocr Metab Disord. 2018. PMID: 30341705
Aggressive pituitary tumours and carcinomas: two sides of the same coin?
Trouillas J, Burman P, McCormack A, Petersenn S, Popovic V, Dekkers O, Raverot G. Trouillas J, et al. Among authors: Petersenn S. Eur J Endocrinol. 2018 Jun;178(6):C7-C9. doi: 10.1530/EJE-18-0250. Epub 2018 Mar 27. Eur J Endocrinol. 2018. PMID: 29588294 Review.
Secondary adrenal insufficiency in pregnancy: any differences?
Petersenn S. Petersenn S. Minerva Endocrinol. 2018 Dec;43(4):446-450. doi: 10.23736/S0391-1977.18.02840-7. Epub 2018 Mar 15. Minerva Endocrinol. 2018. PMID: 29546743 Review.
Pituitary disease management during pregnancy: an overview.
Petersenn S. Petersenn S. Minerva Endocrinol. 2018 Dec;43(4):420-422. doi: 10.23736/S0391-1977.18.02835-3. Epub 2018 Mar 15. Minerva Endocrinol. 2018. PMID: 29546742 Free article. No abstract available.
Editorial : Neuroendocrine neoplasms.
Koch CA, Petersenn S. Koch CA, et al. Among authors: Petersenn S. Rev Endocr Metab Disord. 2017 Dec;18(4):379-380. doi: 10.1007/s11154-018-9441-8. Rev Endocr Metab Disord. 2017. PMID: 29417306 No abstract available.
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P; ESE survey collaborators. McCormack A, et al. Among authors: Petersenn S. Eur J Endocrinol. 2018 Mar;178(3):265-276. doi: 10.1530/EJE-17-0933. Epub 2018 Jan 12. Eur J Endocrinol. 2018. PMID: 29330228
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma.
Heinze B, Fuss CT, Mulatero P, Beuschlein F, Reincke M, Mustafa M, Schirbel A, Deutschbein T, Williams TA, Rhayem Y, Quinkler M, Rayes N, Monticone S, Wild V, Gomez-Sanchez CE, Reis AC, Petersenn S, Wester HJ, Kropf S, Fassnacht M, Lang K, Herrmann K, Buck AK, Bluemel C, Hahner S. Heinze B, et al. Among authors: Petersenn S. Hypertension. 2018 Feb;71(2):317-325. doi: 10.1161/HYPERTENSIONAHA.117.09975. Epub 2017 Dec 26. Hypertension. 2018. PMID: 29279316 Free article.
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM; European Society of Endocrinology. Raverot G, et al. Among authors: Petersenn S. Eur J Endocrinol. 2018 Jan;178(1):G1-G24. doi: 10.1530/EJE-17-0796. Epub 2017 Oct 18. Eur J Endocrinol. 2018. PMID: 29046323 Review.
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial.
Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, Boscaro M, Salvatori R, Yamada M, Tauchmanova L, Roughton M, Ravichandran S, Petersenn S, Biller BMK, Newell-Price J; Pasireotide G2304 Study Group. Lacroix A, et al. Among authors: Petersenn S. Lancet Diabetes Endocrinol. 2018 Jan;6(1):17-26. doi: 10.1016/S2213-8587(17)30326-1. Epub 2017 Oct 12. Lancet Diabetes Endocrinol. 2018. PMID: 29032078 Clinical Trial.
Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.
Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, Melmed S, Mortini P, Wass J, Giustina A; Pituitary Society, Expert Group on Pituitary Tumors. Casanueva FF, et al. Pituitary. 2017 Oct;20(5):489-498. doi: 10.1007/s11102-017-0838-2. Pituitary. 2017. PMID: 28884415 Free PMC article.
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, Scaroni C, Ravichandran S, Kandra A, Biller BMK. Petersenn S, et al. Endocrine. 2017 Jul;57(1):156-165. doi: 10.1007/s12020-017-1316-3. Epub 2017 Jun 9. Endocrine. 2017. PMID: 28597198 Free PMC article. Clinical Trial.
Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, Lanza V, Söderkvist P, Stenman A, Larsson C, Svahn F, Chen JL, Marquard J, Fraenkel M, Walter MA, Peczkowska M, Prejbisz A, Jarzab B, Hasse-Lazar K, Petersenn S, Moeller LC, Meyer A, Reisch N, Trupka A, Brase C, Galiano M, Preuss SF, Kwok P, Lendvai N, Berisha G, Makay Ö, Boedeker CC, Weryha G, Racz K, Januszewicz A, Walz MK, Gimm O, Opocher G, Eng C, Neumann HPH; European-American-Asian Pheochromocytoma-Paraganglioma Registry Study Group. Bausch B, et al. Among authors: Petersenn S. JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223. JAMA Oncol. 2017. PMID: 28384794 Free PMC article.
Anthropometric factors have significant influence on the outcome of the GHRH-arginine test: establishment of normative data for an automated immunoassay specifically measuring 22 kDa human growth hormone.
Deutschbein T, Bidlingmaier M, Schopohl J, Strasburger CJ, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Eur J Endocrinol. 2017 Mar;176(3):273-281. doi: 10.1530/EJE-16-0668. Epub 2016 Dec 8. Eur J Endocrinol. 2017. PMID: 27932410
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM. Findling JW, et al. Among authors: Petersenn S. Endocrine. 2016 Nov;54(2):516-523. doi: 10.1007/s12020-016-0978-6. Epub 2016 May 21. Endocrine. 2016. PMID: 27209465 Free PMC article. Clinical Trial.
Health-related Quality of Life in Patients After Treatment of Cushing's Disease.
Nader S, Burkhardt T, Vettorazzi E, Milian M, Aberle J, Petersenn S, Flitsch J. Nader S, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2016 Mar;124(3):187-91. doi: 10.1055/s-0035-1569340. Epub 2016 Mar 23. Exp Clin Endocrinol Diabetes. 2016. PMID: 27008635
Erratum: Histological criteria for atypical pituitary adenomas--data from the German pituitary adenoma registry suggests modifications.
Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe UJ, Hans VH, Flitsch J, Saeger W, Buslei R. Miermeister CP, et al. Among authors: Petersenn S. Acta Neuropathol Commun. 2016 Feb 29;4:21. doi: 10.1186/s40478-016-0290-y. Acta Neuropathol Commun. 2016. PMID: 26984397 Free PMC article.
Clinical Impact of the Current WHO Classification of Pituitary Adenomas.
Saeger W, Honegger J, Theodoropoulou M, Knappe UJ, Schöfl C, Petersenn S, Buslei R. Saeger W, et al. Among authors: Petersenn S. Endocr Pathol. 2016 Jun;27(2):104-14. doi: 10.1007/s12022-016-9418-7. Endocr Pathol. 2016. PMID: 26860936 Review.
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot study.
Giustina A, Bevan JS, Bronstein MD, Casanueva FF, Chanson P, Petersenn S, Thanh XM, Sert C, Houchard A, Guillemin I, Melmed S; SAGIT Investigator Group. Giustina A, et al. Among authors: Petersenn S. Pituitary. 2016 Feb;19(1):39-49. doi: 10.1007/s11102-015-0681-2. Pituitary. 2016. PMID: 26377024 Free PMC article.
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.
Miermeister CP, Petersenn S, Buchfelder M, Fahlbusch R, Lüdecke DK, Hölsken A, Bergmann M, Knappe HU, Hans VH, Flitsch J, Saeger W, Buslei R. Miermeister CP, et al. Among authors: Petersenn S. Acta Neuropathol Commun. 2015 Aug 19;3:50. doi: 10.1186/s40478-015-0229-8. Acta Neuropathol Commun. 2015. PMID: 26285571 Free PMC article.
Diagnosis of Primary Hypophysitis in Germany.
Honegger J, Schlaffer S, Menzel C, Droste M, Werner S, Elbelt U, Strasburger C, Störmann S, Küppers A, Streetz-van der Werf C, Deutschbein T, Stieg M, Rotermund R, Milian M, Petersenn S; Pituitary Working Group of the German Society of Endocrinology. Honegger J, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2015 Oct;100(10):3841-9. doi: 10.1210/jc.2015-2152. Epub 2015 Aug 11. J Clin Endocrinol Metab. 2015. PMID: 26262437
Treatment of Primary Hypophysitis in Germany.
Honegger J, Buchfelder M, Schlaffer S, Droste M, Werner S, Strasburger C, Störmann S, Schopohl J, Kacheva S, Deutschbein T, Stalla G, Flitsch J, Milian M, Petersenn S, Elbelt U; Pituitary Working Group of the German Society of Endocrinology. Honegger J, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2015 Sep;100(9):3460-9. doi: 10.1210/jc.2015-2146. Epub 2015 Jun 19. J Clin Endocrinol Metab. 2015. PMID: 26091204
Cushing disease: where do we stand, where are we heading?
Fleseriu M, Petersenn S. Fleseriu M, et al. Among authors: Petersenn S. Pituitary. 2015 Apr;18(2):179-80. doi: 10.1007/s11102-015-0647-4. Pituitary. 2015. PMID: 25759331 No abstract available.
Pituitary-directed medical therapy in Cushing's disease.
Petersenn S, Fleseriu M. Petersenn S, et al. Pituitary. 2015 Apr;18(2):238-44. doi: 10.1007/s11102-015-0639-4. Pituitary. 2015. PMID: 25627118 Review.
Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence.
Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, Brue T, Bruzzi P, Casanueva FF, Chanson P, Colao A, Reincke M, Stalla G, Tsagarakis S. Petersenn S, et al. Eur J Endocrinol. 2015 Jun;172(6):R227-39. doi: 10.1530/EJE-14-0883. Epub 2015 Jan 19. Eur J Endocrinol. 2015. PMID: 25599709 Review.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M, Trovato A, Hughes G, Salgado LR, Boscaro M, Pivonello R; Pasireotide B2305 Study Group. Schopohl J, et al. Pituitary. 2015 Oct;18(5):604-12. doi: 10.1007/s11102-014-0618-1. Pituitary. 2015. PMID: 25537481 Free PMC article. Clinical Trial.
Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.
Giustina A, Bevan J, Bronstein M, Casanueva F, Chanson P, Petersenn S, Truong TX, Massien C, Dias-Barbosa C, Guillemin I, Arnould B, Melmed S. Giustina A, et al. Among authors: Petersenn S. Value Health. 2014 Nov;17(7):A355. doi: 10.1016/j.jval.2014.08.754. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200705 Free article. No abstract available.
Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.
Deutschbein T, Fassnacht M, Weismann D, Reincke M, Mann K, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Clin Endocrinol (Oxf). 2015 Jan;82(1):84-90. doi: 10.1111/cen.12590. Epub 2014 Oct 24. Clin Endocrinol (Oxf). 2015. PMID: 25143180
Expression analysis of GADD45γ, MEG3, and p8 in pituitary adenomas.
Binse I, Ueberberg B, Sandalcioglu IE, Flitsch J, Luedecke DK, Mann K, Petersenn S. Binse I, et al. Among authors: Petersenn S. Horm Metab Res. 2014 Aug;46(9):644-50. doi: 10.1055/s-0034-1383566. Epub 2014 Aug 15. Horm Metab Res. 2014. PMID: 25126861
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Petersenn S, et al. J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24800725 Clinical Trial.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM; Pasireotide B2305 Study Group. Pivonello R, et al. Among authors: Petersenn S. Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17. doi: 10.1111/cen.12431. Epub 2014 Mar 27. Clin Endocrinol (Oxf). 2014. PMID: 24533697 Clinical Trial.
Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.
Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prévost G, Maisonobe P, Clermont A; PRIMARYS Investigators. Caron PJ, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90. doi: 10.1210/jc.2013-3318. Epub 2013 Jan 1. J Clin Endocrinol Metab. 2014. PMID: 24423301 Free PMC article. Clinical Trial.
Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.
Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM. Boscaro M, et al. Among authors: Petersenn S. Pituitary. 2014 Aug;17(4):320-6. doi: 10.1007/s11102-013-0503-3. Pituitary. 2014. PMID: 23943009 Free PMC article. Clinical Trial.
High variability in baseline urinary free cortisol values in patients with Cushing's disease.
Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM; Pasireotide B2305 Study Group. Petersenn S, et al. Clin Endocrinol (Oxf). 2014 Feb;80(2):261-9. doi: 10.1111/cen.12259. Epub 2013 Jul 15. Clin Endocrinol (Oxf). 2014. PMID: 23746264 Free PMC article. Clinical Trial.
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S, Farrall AJ, De Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M, Hermosillo Reséndiz K, Hughes G, Hu K, Barkan A. Petersenn S, et al. Pituitary. 2014 Apr;17(2):132-40. doi: 10.1007/s11102-013-0478-0. Pituitary. 2014. PMID: 23529827 Free PMC article. Clinical Trial.
Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.
Berg C, Petersenn S, Walensi M, Möhlenkamp S, Bauer M, Lehmann N, Roggenbuck U, Moebus S, Broecker-Preuss M, Sandalcioglu IE, Stolke D, Sure U, Joeckel KH, Erbel R, Führer D, Mann K; Investigative Group of the Heinz Nixdorf Recall Study. Berg C, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2013 Feb;121(2):125-32. doi: 10.1055/s-0032-1314811. Epub 2013 Jan 21. Exp Clin Endocrinol Diabetes. 2013. PMID: 23338744
Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency.
Benson S, Neumann P, Unger N, Schedlowski M, Mann K, Elsenbruch S, Petersenn S. Benson S, et al. Among authors: Petersenn S. Eur J Endocrinol. 2012 Nov;167(5):679-85. doi: 10.1530/EJE-12-0351. Epub 2012 Aug 28. Eur J Endocrinol. 2012. PMID: 22930487 Clinical Trial.
Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ, Bidlingmaier M. Manolopoulou J, et al. Among authors: Petersenn S. Clin Chem. 2012 Oct;58(10):1446-56. doi: 10.1373/clinchem.2012.188128. Epub 2012 Aug 20. Clin Chem. 2012. PMID: 22908135
Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass.
Unger N, Hinrichs J, Deutschbein T, Schmidt H, Walz MK, Mann K, Petersenn S. Unger N, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):494-500. doi: 10.1055/s-0032-1309007. Epub 2012 Jun 13. Exp Clin Endocrinol Diabetes. 2012. PMID: 22696168
Medical management of Cushing's disease: what is the future?
Fleseriu M, Petersenn S. Fleseriu M, et al. Among authors: Petersenn S. Pituitary. 2012 Sep;15(3):330-41. doi: 10.1007/s11102-012-0397-5. Pituitary. 2012. PMID: 22674211 Free PMC article. Review.
Combination chemotherapy in advanced adrenocortical carcinoma.
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Fassnacht M, et al. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2. N Engl J Med. 2012. PMID: 22551107 Free article. Clinical Trial.
A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group. Colao A, et al. Among authors: Petersenn S. N Engl J Med. 2012 Mar 8;366(10):914-24. doi: 10.1056/NEJMoa1105743. N Engl J Med. 2012. PMID: 22397653 Free article. Clinical Trial.
Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N. Petersenn S, et al. Clin Ther. 2012 Mar;34(3):677-88. doi: 10.1016/j.clinthera.2012.01.015. Epub 2012 Feb 24. Clin Ther. 2012. PMID: 22364824 Clinical Trial.
Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay.
Deutschbein T, Broecker-Preuss M, Flitsch J, Jaeger A, Althoff R, Walz MK, Mann K, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Eur J Endocrinol. 2012 Apr;166(4):613-8. doi: 10.1530/EJE-11-0945. Epub 2012 Jan 3. Eur J Endocrinol. 2012. PMID: 22214924 Clinical Trial.
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C. Poeppel TD, et al. Among authors: Petersenn S. J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9. J Nucl Med. 2011. PMID: 22072704 Free article. Clinical Trial.
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K. Petersenn S, et al. J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14. J Clin Pharmacol. 2012. PMID: 21673137 Clinical Trial.
Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.
Deutschbein T, Matuszczyk A, Moeller LC, Unger N, Yuece A, Lahner H, Mann K, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2011 Oct;119(9):540-3. doi: 10.1055/s-0031-1279704. Epub 2011 Jun 10. Exp Clin Endocrinol Diabetes. 2011. PMID: 21667440
68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax.
Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S. Boy C, et al. Among authors: Petersenn S. Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1224-36. doi: 10.1007/s00259-011-1760-x. Epub 2011 Mar 3. Eur J Nucl Med Mol Imaging. 2011. PMID: 21369945
Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plöckinger U, Petersenn S; German Lanreotide Study Group. Schopohl J, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):156-62. doi: 10.1055/s-0030-1267244. Epub 2010 Nov 17. Exp Clin Endocrinol Diabetes. 2011. PMID: 21086246 Clinical Trial.
Monitoring medical treatment in adolescents and young adults with congenital adrenal hyperplasia: utility of salivary 17α-hydroxyprogesterone day profiles.
Deutschbein T, Unger N, Hauffa BP, Schaaf K, Mann K, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2011 Mar;119(3):131-8. doi: 10.1055/s-0030-1255104. Epub 2010 Aug 5. Exp Clin Endocrinol Diabetes. 2011. PMID: 20690075
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B; German ACC Registry Group. Fassnacht M, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32. doi: 10.1210/jc.2010-0803. Epub 2010 Jul 28. J Clin Endocrinol Metab. 2010. PMID: 20668036
The rational use of pituitary stimulation tests.
Petersenn S, Quabbe HJ, Schöfl C, Stalla GK, von Werder K, Buchfelder M. Petersenn S, et al. Dtsch Arztebl Int. 2010 Jun;107(25):437-43. doi: 10.3238/arztebl.2010.0437. Epub 2010 Jun 25. Dtsch Arztebl Int. 2010. PMID: 20644702 Free PMC article. Review.
Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.
Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K; Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Berg C, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2010 Aug;95(8):3648-56. doi: 10.1210/jc.2009-2570. Epub 2010 May 12. J Clin Endocrinol Metab. 2010. PMID: 20463098
Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Müssig K, Oksüz MO, Dudziak K, Ueberberg B, Wehrmann M, Horger M, Schulz S, Häring HU, Pfannenberg C, Bares R, Gallwitz B, Petersenn S. Müssig K, et al. Among authors: Petersenn S. Horm Metab Res. 2010 Jul;42(8):599-606. doi: 10.1055/s-0030-1253354. Epub 2010 Apr 26. Horm Metab Res. 2010. PMID: 20422506
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group. Petersenn S, et al. J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21. J Clin Endocrinol Metab. 2010. PMID: 20410233 Clinical Trial.
[Arterial hypertension and subclinical Cushing's syndrome].
Fassnacht M, Beuschlein F, Quinkler M, Petersenn S. Fassnacht M, et al. Among authors: Petersenn S. MMW Fortschr Med. 2010 Feb 18;152(7):39-41. MMW Fortschr Med. 2010. PMID: 20364508 German. No abstract available.
[Pheochromocytoma: current diagnostics and treatment].
Quinkler M, Fassnacht M, Petersenn S, Reisch N, Willenberg HS, Diederich S. Quinkler M, et al. Among authors: Petersenn S. MMW Fortschr Med. 2010 Feb 18;152(7):36-8. MMW Fortschr Med. 2010. PMID: 20364507 German. No abstract available.
Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery.
Berg C, Meinel T, Lahner H, Mann K, Petersenn S. Berg C, et al. Among authors: Petersenn S. Eur J Endocrinol. 2010 May;162(5):853-9. doi: 10.1530/EJE-09-0997. Epub 2010 Mar 5. Eur J Endocrinol. 2010. PMID: 20207728
Rationale for treatment and therapeutic options in Cushing's disease.
Stewart PM, Petersenn S. Stewart PM, et al. Among authors: Petersenn S. Best Pract Res Clin Endocrinol Metab. 2009 Dec;23 Suppl 1:S15-22. doi: 10.1016/S1521-690X(09)70004-1. Best Pract Res Clin Endocrinol Metab. 2009. PMID: 20129190 Review.
Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma.
Deutschbein T, Unger N, Jaeger A, Broecker-Preuss M, Mann K, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Clin Endocrinol (Oxf). 2010 Aug;73(2):153-60. doi: 10.1111/j.1365-2265.2009.03761.x. Epub 2009 Dec 18. Clin Endocrinol (Oxf). 2010. PMID: 20039892 Clinical Trial.
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.
Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, Müssig K, Muresan M, Schäffler A, Reisch N, Schott M, Fassnacht M, Opocher G, Klose S, Fottner C, Forrer F, Plöckinger U, Petersenn S, Zabolotny D, Kollukch O, Yaremchuk S, Januszewicz A, Walz MK, Eng C, Neumann HP; European-American Pheochromocytoma Study Group. Erlic Z, et al. Among authors: Petersenn S. Clin Cancer Res. 2009 Oct 15;15(20):6378-85. doi: 10.1158/1078-0432.CCR-09-1237. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825962 Free article.
Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia.
Müssig K, Oksüz MO, Pfannenberg C, Adam P, Zustin J, Beckert S, Petersenn S. Müssig K, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2009 Nov;94(11):4123-4. doi: 10.1210/jc.2009-0927. Epub 2009 Sep 29. J Clin Endocrinol Metab. 2009. PMID: 19789203 No abstract available.
Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.
Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, Young L, Fishman LM, Engel JB, Willenberg HS, Petersenn S, Eisenhofer G, Ehrhart-Bornstein M, Bornstein SR. Ziegler CG, et al. Among authors: Petersenn S. Version 2. Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27. Proc Natl Acad Sci U S A. 2009. PMID: 19717419 Free PMC article.
Expression of ghrelin and its receptor in human tissues.
Ueberberg B, Unger N, Saeger W, Mann K, Petersenn S. Ueberberg B, et al. Among authors: Petersenn S. Horm Metab Res. 2009 Nov;41(11):814-21. doi: 10.1055/s-0029-1233462. Epub 2009 Aug 10. Horm Metab Res. 2009. PMID: 19670151
Saliva as a medium for aldosterone measurement in repeated sampling studies.
Manolopoulou J, Mulatero P, Maser-Gluth C, Rossignol P, Spyroglou A, Vakrilova Y, Petersenn S, Zwermann O, Plouin PF, Reincke M, Bidlingmaier M. Manolopoulou J, et al. Among authors: Petersenn S. Steroids. 2009 Oct;74(10-11):853-8. doi: 10.1016/j.steroids.2009.05.006. Epub 2009 May 27. Steroids. 2009. PMID: 19481102
The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes.
Garcia EA, King P, Sidhu K, Ohgusu H, Walley A, Lecoeur C, Gueorguiev M, Khalaf S, Davies D, Grossman AB, Kojima M, Petersenn S, Froguel P, Korbonits M. Garcia EA, et al. Among authors: Petersenn S. Eur J Endocrinol. 2009 Aug;161(2):307-15. doi: 10.1530/EJE-09-0122. Epub 2009 May 21. Eur J Endocrinol. 2009. PMID: 19460888
Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register.
Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM, Grussendorf M, Reincke M; Participants of the German Acromegaly Register. Petersenn S, et al. Clin Endocrinol (Oxf). 2009 Sep;71(3):400-5. doi: 10.1111/j.1365-2265.2009.03547.x. Epub 2009 Feb 18. Clin Endocrinol (Oxf). 2009. PMID: 19226273
Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.
Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S; Pituitary Society; European Neuroendocrine Association. Giustina A, et al. J Endocrinol Invest. 2008 Sep;31(9):820-38. doi: 10.1007/BF03349263. J Endocrinol Invest. 2008. PMID: 18997495 Review.
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Boscaro M, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2009 Jan;94(1):115-22. doi: 10.1210/jc.2008-1008. Epub 2008 Oct 28. J Clin Endocrinol Metab. 2009. PMID: 18957506 Clinical Trial.
Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test.
Deutschbein T, Unger N, Mann K, Petersenn S. Deutschbein T, et al. Among authors: Petersenn S. Eur J Endocrinol. 2009 Jan;160(1):9-16. doi: 10.1530/EJE-08-0600. Epub 2008 Oct 24. Eur J Endocrinol. 2009. PMID: 18952762
Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation.
Arbeiter AK, Büscher R, Petersenn S, Hauffa BP, Mann K, Hoyer PF. Arbeiter AK, et al. Among authors: Petersenn S. Nephrol Dial Transplant. 2009 Feb;24(2):643-6. doi: 10.1093/ndt/gfn529. Epub 2008 Sep 22. Nephrol Dial Transplant. 2009. PMID: 18809976
Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register.
Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Quabbe HJ, Plöckinger U; Participants of the German Acromegaly Register. Petersenn S, et al. Eur J Endocrinol. 2008 Nov;159(5):525-32. doi: 10.1530/EJE-08-0498. Epub 2008 Aug 28. Eur J Endocrinol. 2008. PMID: 18755874
Lipodystrophy in patients with acromegaly receiving pegvisomant.
Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Bonert VS, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8. doi: 10.1210/jc.2008-0833. Epub 2008 Jul 8. J Clin Endocrinol Metab. 2008. PMID: 18611977
Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge.
Müssig K, Wehrmann M, Horger M, Bares R, Häring HU, Gallwitz B, Petersenn S. Müssig K, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2008 Oct;116(9):554-7. doi: 10.1055/s-2008-1062727. Epub 2008 Apr 1. Exp Clin Endocrinol Diabetes. 2008. PMID: 18523912
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Biller BM, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62. doi: 10.1210/jc.2007-2734. Epub 2008 Apr 15. J Clin Endocrinol Metab. 2008. PMID: 18413427 Free PMC article. Review.
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
Müssig K, Petersenn S, Wehrmann M, Horger M, Vierling P, Häring HU, Gallwitz B. Müssig K, et al. Among authors: Petersenn S. Eur J Gastroenterol Hepatol. 2007 Aug;19(8):719-23. doi: 10.1097/01.meg.0000223908.00987.18. Eur J Gastroenterol Hepatol. 2007. PMID: 17625444
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J; SMS995B2401 Study Group. Mercado M, et al. Among authors: Petersenn S. Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68. doi: 10.1111/j.1365-2265.2007.02825.x. Epub 2007 Apr 25. Clin Endocrinol (Oxf). 2007. PMID: 17465997 Free PMC article. Clinical Trial.
Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K, Gallwitz B, Honegger J, Strasburger CJ, Bidlingmaier M, Machicao F, Bornemann A, Ranke MB, Häring HU, Petersenn S. Müssig K, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):198-202. doi: 10.1055/s-2007-956172. Exp Clin Endocrinol Diabetes. 2007. PMID: 17427111
[Leydig cell tumor as a cause of hirsutism in a postmenopausal woman].
Matuszczyk A, Petersenn S, Lahner H, Haude M, Veit P, Becker JU, Kimmig R, Bockisch A, Mann K. Matuszczyk A, et al. Among authors: Petersenn S. Med Klin (Munich). 2007 Mar 15;102(3):259-62. doi: 10.1007/s00063-007-1032-5. Med Klin (Munich). 2007. PMID: 17345023 German.
The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome.
Hauffa BP, Haase K, Range IM, Unger N, Mann K, Petersenn S. Hauffa BP, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2007 Mar;92(3):834-40. doi: 10.1210/jc.2006-1011. Epub 2006 Dec 27. J Clin Endocrinol Metab. 2007. PMID: 17192298 Clinical Trial.
Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients.
Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HP, Schmid KW, Mann K. Walz MK, et al. Among authors: Petersenn S. Surgery. 2006 Dec;140(6):943-8; discussion 948-50. doi: 10.1016/j.surg.2006.07.039. Surgery. 2006. PMID: 17188142
The German Acromegaly Registry: description of the database and initial results.
Reincke M, Petersenn S, Buchfelder M, Gerbert B, Skrobek-Engel G, Franz H, Lohmann R, Quabbe HJ. Reincke M, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2006 Oct;114(9):498-505. doi: 10.1055/s-2006-948313. Exp Clin Endocrinol Diabetes. 2006. PMID: 17115347 Clinical Trial.
Gadolinium as an alternative contrast agent during cardiac catheterization in patient with iodine-induced hyperthyroidism.
Matuszczyk A, Hahn S, Böse D, Eggebrecht H, Schmermund A, Quadbeck B, Wieneke H, Petersenn S, Janssen OE, Mann K. Matuszczyk A, et al. Among authors: Petersenn S. Exp Clin Endocrinol Diabetes. 2006 Jun;114(6):336-8. doi: 10.1055/s-2006-924262. Exp Clin Endocrinol Diabetes. 2006. PMID: 16868894
[Diagnosis and therapy of endocrine hypertension].
Unger N, Petersenn S, Mann K. Unger N, et al. Among authors: Petersenn S. Med Klin (Munich). 2006 Mar 22;101 Suppl 1:170-2. Med Klin (Munich). 2006. PMID: 16802547 German.
Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery.
Fasshauer M, Lincke T, Witzigmann H, Kluge R, Tannapfel A, Moche M, Buchfelder M, Petersenn S, Kratzsch J, Paschke R, Koch CA. Fasshauer M, et al. Among authors: Petersenn S. BMC Cancer. 2006 Apr 27;6:108. doi: 10.1186/1471-2407-6-108. BMC Cancer. 2006. PMID: 16643652 Free PMC article.
Efficacy and limits of somatostatin analogs.
Petersenn S. Petersenn S. J Endocrinol Invest. 2005;28(11 Suppl International):53-7. J Endocrinol Invest. 2005. PMID: 16625846 Review.
Endoscopic treatment of large primary adrenal tumours.
Walz MK, Petersenn S, Koch JA, Mann K, Neumann HP, Schmid KW. Walz MK, et al. Among authors: Petersenn S. Br J Surg. 2005 Jun;92(6):719-23. doi: 10.1002/bjs.4964. Br J Surg. 2005. PMID: 15856491
Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasias.
Walz MK, Peitgen K, Diesing D, Petersenn S, Janssen OE, Philipp T, Metz KA, Mann K, Schmid KW, Neumann HP. Walz MK, et al. Among authors: Petersenn S. World J Surg. 2004 Dec;28(12):1323-9. doi: 10.1007/s00268-004-7667-y. Epub 2004 Nov 11. World J Surg. 2004. PMID: 15517476
Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.
Schmidt IL, Lahner H, Mann K, Petersenn S. Schmidt IL, et al. Among authors: Petersenn S. J Clin Endocrinol Metab. 2003 Sep;88(9):4193-8. doi: 10.1210/jc.2002-021897. J Clin Endocrinol Metab. 2003. PMID: 12970286 Clinical Trial.
Characterization of the human somatostatin receptor type 4 promoter.
Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM. Petersenn S, et al. Mol Cell Endocrinol. 2002 Feb 25;188(1-2):75-83. doi: 10.1016/s0303-7207(01)00747-x. Mol Cell Endocrinol. 2002. PMID: 11911948
Differentiation and regulation of the corticotropic pituitary cell.
Petersenn S, Schulte HM. Petersenn S, et al. Eur J Clin Invest. 2000 Dec;30 Suppl 3:10-3. doi: 10.1046/j.1365-2362.2000.0300s3010.x. Eur J Clin Invest. 2000. PMID: 11281361 Review.